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Background: The aim of this study was to investigate the reproducibility of intra- and inter-observer interpretation
of [18F]choline positron emission tomography/computed tomography examinations in patients suffering from
biochemically recurrent prostate cancer following curative treatment.
Methods: A total of 60 patients with biochemical recurrence after curative treatment were included in this
bicentric study. The interpretations were based on a systematic analysis of several anatomic regions and all the four
nuclear medicine physicians used identical result consoles. The examinations were interpreted with no knowledge
of the patients' clinical context. Two months later, a second interpretation of all these examinations was performed
using the same method, in random order.
Results: To evaluate local recurrences, when the prostate is in place, the results showed moderate inter- and
intra-observer reproducibility: concordance of all 4 physicians has a Fleiss' kappa coefficient of 0.553 with a
confidence interval of (0.425 to 0.693). For patients who had had a prostatectomy, there was excellent concordance
for the negative examinations. For the lymphatic basin, inter- and intra-observer reproducibility was excellent with a
Fleiss' kappa coefficient of 0.892 with a confidence interval of (0.788 to 0.975). The lymphatic sub-group analysis
was also good. For the lymphatic groups in the right or left hemi-pelves, all Fleiss' kappa and Cohen's kappa
coefficients are varying from 0.760 to 1 with narrow confidence intervals from (0.536 to 0.984) to (1 to 1) in favour
of good/excellent inter-observer reproducibility. To evaluate bone metastasis, inter-observer reproducibility was
good with a Fleiss' kappa coefficient of 0.703 and a confidence interval of (0.407 to 0.881).
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Conclusion: Our study is at time the only one on the reproducibility of interpretation of [18F]choline positron
emission tomography/computed tomography examinations, which is a key examination for the treatment of
patients suffering biochemical recurrence of prostate cancer. Interpretation of the [18F]choline positron emission
tomography/computed tomography examination is not so useful at prostate level in patients not previously treated
with prostatectomy but has a great interest on patients treated by prostatectomy. It showed good concordance in
the interpretation of sub-diaphragmatic lymphatic recurrences as well as in bone metastasis.
Keywords: 18F; choline positron emission tomography; Computed tomography; Prostate cancer; Biochemical
recurrence; Inter- and intra-observer reproducibilityBackground
Prostate cancer is the most frequent cancer in men in
Western Europe and North America and is estimated to
cause death of one of ten men suffering from this cancer
[1,2]. For patients suffering from prostate cancer, recur-
rence after radical treatment is common during the first
10 years. The risk of recurrence is 20% to 50% in pa-
tients treated by radical prostatectomy, and 30% to 40%
in patients treated with external radiotherapy [3,4].
At present, the detection of recurrent prostate cancer
in patients who had curative treatment is done by blood
assay of prostate specific antigen (PSA) levels [5–7].
There are currently several possible imaging modalities,
often complementary, for detecting recurrence of pros-
tate cancers, including pelvic MRI, endorectal ultra-
sound, bone scintigraphy, thoracic-abdomino-pelvic
(TAP) CT-scan and [18F]choline positron emission tom-
ography/computed tomography (PET/CT).
Numerous authors studied the sensitivity and specifi-
city of [18F]choline PET/CT for the biochemical recur-
rence of prostate cancers [8–10], but none of them
investigated the variability of interpretations of [18F]
choline PET/CT examinations. The aim of this bicentric
retrospective observational study was to evaluate the
inter- and intra-observer variability of interpretations of
[18F]choline PET/CT examinations in patients suffering




From all patients that had a [18F]choline PET/CT exam-
ination at our two centres from 2011 to 2013, we retro-
spectively included 60 patients that met the following
inclusion criteria:
– Males with biochemical recurrence of PSA after
curative treatment for prostate cancer including
total prostatectomy, external radiotherapy or
radium treatment. Biochemical recurrence was
defined by PSA level over 0.2 ng/ml if initial
treatment was prostatectomy, or PSA level over2 ng/ml if initial treatment was conformational
radiotherapy [5,6].
– [18F]choline PET/CT examination with an
acquisition protocol including at least one dynamic
examination and a later full body examination.
The patient data were anonymized (Table 1). All pa-
tients provided informed consent for their participation
in this study. Our study protocol was approved by the
Institutional Review Boards of both centres.Acquisition protocol
The acquisition protocol for the [18F]choline PET/CT
examination was identical for all patients, but different
equipment were used at the two centres. For 52 patients
at one centre, a PET-CT Scanner (Discovery 690, Gen-
eral Electric, Wakacha, IL, USA) was used with three-
dimensional ordered subsets expectation maximization
(3D-OSEM) reconstructions having 2 iterations and 24
subsets. For eight patients at the other second centre, a
Biograph Duo PET/CT Scanner (Siemens AG, Munich,
Germany) with 3D-OSEM reconstructions having three
iterations and eight subsets. Six to eight bed positions
per patient were acquired from the head to the upper
third of the thighs. The PET images were corrected for
random coincidences, scatter and attenuation using the
CT scan data.
The patients had been fasting for 6 h, non-hydrated,
and emptied their bladder before the examination. Inter-
pretation was based on an early dynamic image acquisi-
tion, done after a bolus injection of [18F]choline (activity
5 MBq/kg) under the camera, and on a late image acqui-
sition. The image acquisitions included 10 consecutive
1-min recordings on a single bed centred on the pelvis.
Dynamic acquisition started about 2 min after the injec-
tion in list mode. An early acquisition centred on the ab-
domen and pelvis was taken immediately afterwards,
from the hepatic dome to beneath the ischia. Immedi-
ately after this series of images, the patient was injected
with 20 mg of furosemide and was orally hydrated. After
40 min of rest in a chair, a late whole-body acquisition
was taken, from the vertex to the mid-thigh.




Min to max 57 to 86
Median 72
Initial PSA level (ng/ml)
Average 14.77
Min to max 1.5 to 63
Median 9.80
PSA level; at the time of the PET/CT request (ng/ml)
Average 6.43

















Surg. A nd RT 8
Surg. RT and HT 2
RT only 34
Brachytherapy only 5
Time to double PSA (months)
>12 months 6







Min to max 0.05 to 15.45
Median 2.03
PSA, prostatic specific antigen; TNM, tumor nodes metastasis; RT, radiotherapy;
HT, hormone therapy.
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The 60 patient examinations were interpreted separately
by four nuclear medicine specialists: two senior physi-
cians (CG, CC) and two junior physicians (JD, CP). The
senior physicians had at least 3 years of experience in
interpreting [18F]choline PET/CT results, whereas the
junior physicians had 1 year of experience in interpreting
[18F]choline PET/CT results.
The examinations were interpreted with no knowledge
of the patients' clinical context. Each physician made an
initial interpretation of the anonymized examinations.
Images were interpreted visually based on averaged ac-
quisitions of two time intervals: 1 to 5 and 6 to 10 min.
The first interval enabled visualization without distor-
tions caused by bladder activity. The interpretations
were based on a systematic analysis of the following ana-
tomic regions: (i) the prostatic bed or the prostate, (ii)
the periprostatic lymph node areas, (iii) the perirectal
lymph node areas, (iv) medial iliac lymph node areas, (v)
lateral iliac lymph node areas and the iliac bifurcation
lymph node area, (vi) common iliac lymph node areas,
(vii) lumboaortic and mesenteric lymph node areas, (viii)
and supra-diaphragmatic lymph nodes and remote meta-
static sites: bone, lung, liver, and central nervous system.
Each physician had to visually evaluate the type of foci
of increased uptake, with binary rating of ‘0’ for benign/
non-significant or ‘1’ for malignant/high-risk, for each
anatomical region described above. At least 2 months
later, a second interpretation of all pre-existing examina-
tions was performed by each physician separately using
the same method, in different order (defined by a ran-
dom number generator software).
Statistical analysis
The analyses were performed using the software STATA
version 12.0 (College Station, StataCorp LP, TX, USA).
The main assessment criterion was the reproducibility of
inter- and intra-observer interpretation of [18F]choline
PET/CT examinations, evaluated by the kappa (κ) statis-
tical test [11]. Cohen's Kappa coefficient (reproducibility
between two observers) and the Fleiss' Kappa coefficient
(reproducibility between four observers) indicated repro-
ducibility of interpretations: κ > 0.81 is excellent, 0.80
> κ > 0.61 is good, 0.60 > κ > 0.41 is moderate, 0.40 < κ <
0.00 is average, and κ < 0.00 is poor [12]. The kappa co-
efficients were recorded with their confidence intervals
(CI). The null hypothesis was that κ = 0, i.e. no inter- or
intra-observer agreement other than pure chance. More-
over, in this study, the p values are lower than 5%. For
this reason, our results are statistically significant. How-
ever, since this study was not a randomized study, the
alpha risk is not applicable (as per statistical rules).
The overall conclusion of the PET examination included
analysis of the prostate, supra- and sub-diaphragmatic
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nervous system) for a given patient. Statistical analyses
were also done independently for each of the aforemen-
tioned anatomic regions. Other calculations were made on
the pelvic lymphatic nodes of the right and left hemi-
pelves. The pelvic lymphatic nodes included all the sub-
diaphragmatic lymphatic areas (excluding the inguinal
nodes) which were found to be positive or negative by each
physician. The right and left hemi-pelves included the
common iliac lymph nodes, iliac bifurcation lymph nodes,
lateral and medial iliac lymph nodes, periprostatic and ob-
turator lymph nodes on the same side.
Results
The inter-observer reproducibility for the overall conclu-
sion of the [18F]choline PET/CT examination was mod-
erate. Reproducibility between the four physicians had a
kappa of 0.499 (CI 0.350 to 0.652). Reproducibility be-
tween the two senior physicians had a kappa of 0.454,
whereas reproducibility between the two junior physi-
cians had a kappa of 0.537.
When the prostate is in place, the inter-observer re-
producibility between all four physicians was moderate
with a kappa of 0.553 (CI 0.425 to 0.693). The intra-
observer reproducibility was moderate for two physi-
cians and was poor/average for the other two physicians.
For the evaluation of local recurrences for the prostatec-
tomy bed, the kappa coefficient could be calculated but would
have no sense. Indeed, only 3 of the 19 operated patients were
considered to be positive for the prostatectomy bed. Among
these three patients, all four nuclear physicians concluded on
recurrence for two patients, and only two nuclear physicians
concluded on recurrence for the third patient.
For the pelvic lymph nodes, there was excellent inter-
observer reproducibility with a kappa of 0.892 (CI 0.788 to
0.975). For the lymph nodes in the right and left hemi-
pelves, there was good to excellent inter-observer reprodu-
cibility with a kappa between 0.760 (CI 0.536 to 0.984) and
1 (CI 1 to 1). The left medial iliac lymph nodes had lower
inter-observer reproducibility with a kappa of 0.362
(CI −0.008 to 0.662). For some locations, such as the left
periprostatic lymph node, the kappa coefficient could not
be calculated as there was no positive focus. All the other
lymph nodes (lateral iliac lymph nodes iliac bifurcation
lymph nodes, common iliac lymph nodes, lumbo-aortic
mesenteric lymph nodes) had good reproducibility between
the four physicians with kappa between 0.559 (CI −0.021
to 1) and 0.806 (CI 0.587 to 0.965).
For the evaluation of metastatic dissemination, inter-
observer reproducibility between the four nuclear physi-
cians was good with a kappa of 0.703 (CI 0.407 to
0.881). For the other secondary locations, lungs and
liver, mediastinal lymph nodes, the kappa could not be
calculated.The intra-observer reproducibility of interpretations of
the overall conclusion of the [18F]choline PET/CT exam-
ination was good except for one of the junior physicians.
Discussion
The precise identification of the site of biochemical recur-
rence of prostate cancer is important as it enables initi-
ation of curative treatments such as radiotherapy and
surgery. These treatments help delay the introduction of
hormone therapy, a long-term treatment with only tem-
porary efficacy and with many side effects. In a prospect-
ive study of 72 patients, Rigatti et al. [13] showed that
salvage lymphadenectomy guided by choline PET for pa-
tients suffering biochemical recurrence after curative
treatment has raised the prostate cancer remission level
by 35% in 5 years. This study shows that progression-free
survival is increased by appropriate treatment.
[18F]Choline PET/CT has an important position in the
diagnosis prior to the treatment of prostate cancers in a
situation of biochemical recurrence, considering its high
level of sensitivity. Giovacchini et al [8] showed a rate of
positive diagnosis after prostatectomy of 83% when the
PSA level is above 3 ng/ml.
The reproducibility of interpretation of this examin-
ation becomes essential when the result leads to a deci-
sion on choice of therapy. As far as we know, our study
is the first to observe the reproducibility of interpret-
ation of [18F]choline PET/CT examinations.
In our study, the inter-observer reproducibility of the
PET overall conclusion for [18F]choline PET/CT exami-
nations was moderate, and it is particularly lowered by
the poor reproducibility of the prostate results.
In the pelvis, evaluation of intraprostatic recurrence is
difficult, which was the case in our study (Figure 1). For
initial diagnosis, a study showed that [18F]choline PET/CT
has a high sensitivity in detecting prostate cancer of 86.5%
but a lower specificity of 61.9% [14]. Numerous studies
showed that differentiating between malignant and benign
intraprostatic lesion is difficult using [18F]choline PET/CT.
Some authors showed many false-positive cases linked with
prostatisis [15]. For this reason, it is likely that in our study,
the different nuclear physicians interpreted the false-
positive results differently because of the low specificity of
[18F]choline PET/CT when the prostate is in place. Other
authors showed an overlap of max standardized uptake
values (SUVs) between cancers and benign lesions [16].
This explains why reproducibility is mediocre, as shown by
our discordances in interpretation between physicians
when the prostate is still in place, which was the case for
most of our patients. These results demonstrate the need
to define more robust interpretation criteria than those
currently in use.
In order to solve this issue, some authors proposed an in-
terpretation method, using the kinetics of choline capture in
Figure 1 [18F]choline PET (a) and [18F]choline PET/CT (b) of axial
section of pelvis. This shows a heterogeneity of increased uptake
in the prostate. This figure also illustrates a case of discordance
between the nuclear medicine physicians (one junior in favor of
recurrence and the three other nuclear medicine physicians not in
favor of a recurrence).
Figure 2 [18F]choline PET (a) and [18F]choline PET/CT (b) of axial
section of pelvis. This shows a hypermetabolic focus in the
prostatectomy bed on the right, suspecting recurrence. The figure
also illustrates a case of full concordance between the four nuclear
medicine physicians.
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nign tumour or prostatitis. Authors showed that choline
capture takes place very quickly during the first 30 min and
then it remains on a plateau if there is a cancerous lesion.
However, this study does not specify whether this has im-
proved sensitivity and specificity [17]. For initial diagnosis, a
study showed that MRI (MR imaging +3D MR spectro-
scopic imaging) has a better sensitivity of prostate cancer
than [18F]choline PET/CT examination [18]. However, we
did not find any studies about the reproducibility of inter-
pretation of prostatic MRI examinations.In the prostatectomy bed, our results of reproducibility
are excellent but concern only 3 positive cases out of 19
patients (Figure 2). Indeed, concordance was 100% for the
16 patients considered to be negative. For the only dis-
cordant patient in both inter- and intra-observer status for
two physicians, it should be noted that the patient had a
total hip arthroplasty which affected the interpretation.
A study shows that [18F]choline PET/CT demonstrates
sensitivity, specificity, negative predictive value (NPV),
and positive predictive value (PPV) of percentages 73%,
88%, 92%, and 61%, respectively, after surgery compar-
able to magnetic resonance imaging (MRI) at 3 T for a
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patients who were candidates for salvage radiotherapy with
a curative aim, but these studies do not specify reproduci-
bility. In conclusion, reproducibility is excellent for nega-
tive cases, which supports the NPV of the examination.
In the pelvis lymph nodes, our inter- and intra-
observer interpretation reproducibility was excellent
(Figure 3). These results are coherent with studies con-
cerning the performance of this examination. Scattoni
et al. showed that [11C]choline has a good PPV [10]. De
Jong et al. showed the [11C]choline PET had a sensitivity,
specificity, and accuracy of 80%, 96%, and 93%, respect-
ively, for detecting lymphatic metastasis [9]. The nuclear
medicine physicians in our study obtained good repro-
ducibility of interpretation in both inter- and intra-
observer situations in sub-diaphragmatic lymph nodes.
This supports the results of other studies on the contri-
bution of [18F]choline PET/CT in detecting abdomino-
pelvic lymphatic recurrence in a situation of biochemical
recurrence [13]. Another study showed [18F]choline
PET/CT examination which in a situation of recurrence
found a high PPV estimated at 86% and a less sensitivity
at 72%, linked to micrometastatic involvement [10].
These results are all the more significant in that repro-
ducibility was good, or even excellent for both seniors
and juniors. This leads to the assumption that any nu-
clear medicine physician with [18F]fluorodeoxyglocose
(FDG)/PET experience can interpret an [18F]choline
PET/CT examination just as efficiently, particularly for
detecting sub-diaphragmatic lymphatic recurrences [5,6].
These conclusions apply to the various lymphatic areas
as shown in Tables 2 and 3. The limits of our study con-
cern several points. The use of kappa coefficients for the
inter-observer reproducibility was not possible in some lo-
cations, given the low prevalence of the positivity of the
expected/researched sign of our sample. Few or no
tumour involvement was suspected not only in someFigure 3 [18F]choline CT (a) and [18F]choline PET/CT (b) of abdomino-
on an adenopathy of the left iliac bifurcation, suspecting recurrence. This fi
nuclear medicine physicians.locations, such as lung, liver, muscles, and mediastinal and
inguinal nodes, but also in medial left iliac lymph nodes.
The low number of positive nodes might explain the poor
kappa coefficient in this latter location. Some wide confi-
dence intervals are giving us another limit of this study, as
is the case for the left and right medial iliac lymph nodes.
Moreover, intra-observer reproducibility would certainly
have been better if we had had access to each patient's
clinical data. However, the aim of our study was to study
the reproducibility of interpretation of foci using the [18F]
choline PET/CT examination with different physicians,
and not to validate the medical interpretation as such.
In our study, we did not have a Gold standard (prostatic
or lymphatic biopsies). In our series, for some patients (22
of them), salvage treatment was radiotherapy or hormone
therapy which did not give us access to anatomopatholo-
gical results. A lumbo-aortic lymphatic salvage dissection
was carried out for only three patients. For these three pa-
tients, the lymph nodes were considered suspicious by all
the four physicians and this was confirmed by the anato-
mopathological result. Therefore, we cannot provide fig-
ures for sensitivity and specificity. However, the objective
of our study was to answer the following question: Is there
a focus of increased uptake indicating suspected recur-
rence? Our results show that concordance for a negative
examination was excellent. It must be improved to con-
firm the reality of recurrence, particularly in cases where
the prostate is in place; the results being better for lymph-
atic areas or the prostatectomy bed.
Conclusion
The reproducibility of interpretation of imaging examina-
tions is important because these examinations lead to de-
cisions on the treatment to be given to patients. To our
knowledge, our study is the first to report reproducibility
of interpretation of [18F]choline PET/CT examinations.
This study carried out on patients with prostate cancer inpelvic coronal section. This shows a hypermetabolic focus projected
gure also illustrates a case of full concordance between the four
Table 2 Inter-observer reproducibility of binary interpretations (negative/benign/non-significant or positive/malignant/
high-risk)
Locations Inter-observer agreement at first interpretation
kappa [confidence interval]
Two senior physicians Two junior physicians All four nuclear physicians
Prostate and prostatic bed 0.337 [0.115 to 0.559] 0.661 [0.473 to 0.848] 0.550 [0.425 to 0.692]
Prostate 0.328 [0.096 to 0.561] 0.643 [0.444 to 0.842] 0.553 [0.425 to 0.693]
Prostatectomy bed NA NA NA
Pelvic LN 0.921 [0.812 to 1.000] 0.889 [0.766 to 1.000] 0.892 [0.788 to 0.975]
R hemi-pelvic LN 1.000 [1.000 to 1.000] 0.777 [0.569 to 0.896] 0.833 [0.626 to 0.958]
L hemi-pelvic LN 0.795 [0.571 to 1.000] 0.760 [0.536 to 0.984] 0.819 [0.600 to 0.942]
R periprostatic LN 0.792 [0.396 to 1.000] 1.000 [1.000 to 1.000] 0.885 [−0.004 to 1.000]
L periprostatic LN 0.000 [0.000 to 1.000] 0.000 [0.000 to 1.000] 0.212 [−0.008 to 0.328]
R medial iliac LN 0.550 [0.107 to 0.993] 0.550 [0.107 to 0.993] 0.646 [0.165 to 0.937]
L medial iliac LN −0.023 [−0.070 to 0.025] 0.487 [−0.113 to 1.000] 0.362 [−0.008 to 0.662]
R lateral iliac LN and bifurcation iliac LN 0.880 [0.648 to 1.000] 0.815 [0.568 to 1.000] 0.774 [0.494 to 0.948]
L lateral iliac LN and bifurcation iliac LN 0.659 [0.036 to 1.000] 0.483 [−0.131 to 1.000] 0.559 [−0.021 to 1.000]
R common iliac LN 0.848 [0.557 to 1.000] 0.677 [0.381 to 0.973] 0.669 [0.269 to 0.891]
L common iliac LN 0.699 [0.379 to 1.000] 0.838 [0.620 to 1.000] 0.806 [0.587 to 0.965]
Inguinal LN NA NA NA
Lumboaortic LN 0.900 [0.707 to 1.000] 0.815 [0.568 to 1.000] 0.888 [0.646 to 1.000]
Mediastinal LN NA NA NA
Bone 0.712 [0.445 to 0.978] 0.608 [0.323 to 0.893] 0.703 [0.407 to 0.881]
PET overall conclusion 0.455 [0.235 to 0.674] 0.537 [0.288 to 0.786] 0.499 [0.350 to 0.652]
The inter-observer reproducibility is indicated by kappa (κ) (and confidence interval) for different anatomic regions. NA indicates categories where the sign was
not found at all and therefore the kappa could not be calculated. κ > 0.80 is excellent; 0.61 < κ < 0.80 is good; 0.60 < κ < 0.41 is moderate; κ < 0.40 is average. LN,
lymph nodes; R, right; L, left.
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agreement in their interpretation of sub-diaphragmatic
lymphatic recurrences. On the other hand, interpretation
of the [18F]choline PET/CT examination is not so useful
at prostate level in patients not previously treated withTable 3 Intra-observer reproducibility of binary interpretation
high-risk
Locations Intra-observer agreement between first
kappa [confidence interval]
Senior 1 (CG) Senior 2 (C
Prostate and bed 0.493 [0.237 to 0.749] 0.789 [0.629
Prostatectomy bed NA NA
Prostate 0.528 [0.252 to 0.805] 0.741 [0.561
Pelvic LN 0.812 [0.656 to 0.967] 1.000 [1.000
R hemi-pelvic LN 0.715 [0.485 to 0.944] 0.932 [0.799
L hemi-pelvic LN 0.658 [0.380 to 0.935] 0.795 [0.571
PET overall conclusion 0.626 [0.432 to 0.820] 0.741 [0.561
The inter-observer reproducibility is indicated by kappa (κ) (and confidence interva
0.60 < κ < 0.41 is moderate; κ < 0.40 is average. LN, lymph nodes; R, right; L, left.prostatectomy, but is of great interest in patients treated
by prostatectomy. This is probably an argument in favour
of systematic dual interpretation. Other reproducibility
studies taking into account standardized uptake values
(SUVs) are needed.s (negative/benign/non-significant or positive/malignant/
and second interpretation
C) Junior 1 (JD) Junior 2 (CP)
to 0.949] 0.798 [0.645 to 0.951] 0.534 [0.312 to 0.755]
NA NA
to 0.920] 0.755 [0.585 to 0.925] 0.548 [0.320 to 0.776]
to 1.000] 0.925 [0.823 to 1.000] 0.889 [0.766 to 1.000]
to 1.000] 0.777 [0.569 to 0.896] 0.839 [0.662 to 1.000]
to 1.000] 0.870 [0.693 to 1.000] 0.640[0.376 to 0.904]
to 0.920] 0.574 [0.368 to 0.780] 0.645 [0.421 to 0.869]
l) for different anatomic regions. κ > 0.80 is excellent; 0.61 < κ < 0.80 is good;
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